A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium

Expert Opinion on Drug Safety

Volumn 13, Issue 12, 2014, Pages 1733-1742

  Gentile, Salvatore ^a,b  

^a ASL Salerno   (Italy)

^b University on Naples   (Italy)

Author keywords

Antipsychotics; Aripiprazole; Breastfeeding; Pregnancy; Puerperium; Safety; Teratogenicity

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

AMNIOCENTESIS; AUTISM; BIPOLAR I DISORDER; BIRTH; BIRTH DEFECT; BRAIN DEVELOPMENT; BREAST FEEDING; BREAST MILK; DETERIORATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MECHANISM; DRUG SAFETY; ELIMINATION HALF-LIFE; FIRST TRIMESTER PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEWBORN INTENSIVE CARE; PERSECUTORY DELUSION; PNEUMONIA; PREGNANCY; PREMATURITY; PRENATAL EXPOSURE; PROLACTIN RELEASE; PUERPERIUM; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SPONTANEOUS ABORTION; SYMPTOM; SYSTEMATIC REVIEW; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; THOUGHT DISORDER; WEIGHT GAIN; ANIMAL; DRUG EFFECTS; FEMALE; PSYCHOTIC DISORDERS;

ANIMALS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; PIPERAZINES; POSTPARTUM PERIOD; PREGNANCY; PSYCHOTIC DISORDERS; QUINOLONES; SCHIZOPHRENIA;

EID: 84912019480     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.951325     Document Type: Review

References (80)

1. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990;14:522-55
2. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996;274:740-3
3. Bunney WE, Meltzer HY. Schizophrenia: overview. Clin Neurosci 1995;3:55-6
4. Hafner H, Maurer K, Loffler W, et al. The epidemiology of early schizophrenia. Influence of age and gender on onset and early course. Br J Psychiatry 1994;23(Suppl):29-38
5. Jablensky AV, Morgan V, Zubrick SR, et al. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005;162:79-91
6. Hizkiyahu R, Levy A, Sheiner E. Pregnancy outcome of patients with schizophrenia. Am J Perinatol 2010;27:19-23
7. Webb RT, Pickles AR, King-Hele SA, et al. Parental mental illness and fatal birth defects in a national birth cohort. Psychol Med 2008;38:1495-503
8. Wan MW, Penketh V, Salmon MP, et al. Content and style of speech from mothers with schizophrenia towards their infants. Psychiatry Res 2008;159:109-14
9. Coverdale JH, Turbort SH, Roberts H. Family planning needs and STD risk behaviours of female psychiatric outpatients. Br J Psychiatry 1997;171:69-72
10. Keck PE Jr, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001;85:645-61
11. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998;50:143-51
12. U.S. Census Bureau Population Estimates by Demographic Characteristics. Table 2: Annual Estimates of the Population by Selected Age Groups and Sex for the United States: April 1, 2000 to July 1, 2004 (NC-EST2004-02) Source: Population Division, U.S. Census Bureau Release Date: June 9, 2005. Available from: http://www.census.gov/popest/national/asrh/[Accessed 15 June 2014]
13. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
14. Boden R, Lundgren M, Brandt L, et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ 2012;345:e7085
15. Gentile S. Atypical antipsychotic for the treatment of bipolar disorder. More shadows than lights. CNS Drugs 2007;21:367-87
16. Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 2007;27:35-45
17. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1992;21(2 Suppl):S106-15
18. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implication for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-6
19. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? Am J Psychiatry 2001;158:360-9
20. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123-34
21. Gentile S. The clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother 2004;38:1265-71
22. Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011;24:34-40
23. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-40
24. Reynolds GP. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatr Scand 1994;380(suppl):36-40
25. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel antipsychotic drug. Pharmacotherapy 2004;24:212-28
26. DrugLib.com. Abilify (Aripiprazole)-description and clinical pharmacology. Available from: http://www.druglib.com/druginfo/abilify/description-pharmacology/[Accessed: 18 April 2014]
27. emc. Abilify 7.5 mg/ml solution for injection (intramuscular). Available from: http://www.medicines.org.uk/emc/medicine/20802/SPC/Abilify+7.5+mg+ml +solution+for+injection+(intramuscular)/[Accessed 30 April 2014]
28. Gopalakrishna G, Aggarwal A, Lauriello J. Long-Acting injectable aripiprazole: how might it fit in our tool box? Clin Schizophr Relat Psychoses 2013;7:87-92
29. Motiwala FB, Siscoe KS, El-Mallakh RS. Review of depot aripiprazole for schizophrenia. Patient Prefer Adherence 2013;7:1181-7
30. Abilify. Full prescribing information. Available from: http://www.otsuka-us. com/Documents/Abilify.PI.pdf [Accessed 2 May 2014]
31. Berman RM, Fava M, Thase ME. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14(4):197-206
32. Medscape Multispeciality. FDA approves aripiprazole to treat irritability in autistic children. Available from: http://www. medscape.com/viewarticle/713006 [Accessed 18 April 2014]
33. Mc Gavin JK, Goa LK. Aripiprazole. CNS Drugs 2002;16:779-386
34. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
35. Keck PE, Calabrese JR, McIntyre RS, et al. for the Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480-91
36. Gentile S. Long term atypical antipsychotics treatment and risk of weight gain. A literature analysis. Drug Saf 2006;29:303-19
37. Gentile S. Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 2009;10:527-42
38. Gentile S. Quality of life and weight related issues in patients treated for schizophrenia: focus on aripiprazole. Neuropsychiatr Dis Treat 2009;5:117-25
39. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-73
40. Product information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ; 2003
41. Mendhekar DN, Sunder KR, Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord 2006;8:299-300
42. Mervak B, Collins J, Valenstein M. Case report of aripiprazole usage during pregnancy. Arch Womens Ment Health 2008;11:249-50
43. Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother 2006;40:575
44. Watanabe N, Kasahara M, Sugibayashi R, et al. Perinatal use of aripiprazole. A case report. J Clin Psychopharmacol 2011;31:377-9
45. Gentile S, Bellantuono C, Tofani S. Aripiprazole in pregnancy. A case report and a literature review. J Clin Psychopharmacol 2011;31:531-2
46. Lutz UC, Hiemke C, Wiatr G, et al. Aripiprazole in pregnancy and lactation. A case report. J Clin Psychopharmacol 2010;30:204-5
47. Widschwendter CG, Hofer A. Aripiprazole use in early pregnancy: A case report. Pharmacopsychiatry 2012;45:299-300
48. Nguyen T, Teoh SL, Hackett P, Ilett K. Placental transfer of aripiprazole. Aust N Z J Psychiatry 2011;45:500-1
49. Nordeng H, Gjerdalen G, Brede WR, et al. Transfer of aripiprazole to breast milk. A case report. J Clin Psychopharmacol 2014;34:272-5
50. Derganc M, Savs AP. The use of aripiprazole during pregnancy: A case report. Eur Psychiatry 2013;28(Suppl 1):1
51. Doulgeraki G, Karadima D, Kalogiratos G, et al. Pregnancy, aripiprazole and psychotherapy. Eur Psychiatry 2007;22:S206
52. Bellet F, Beyens MN, Bernard N, et al. Pregnancy outcome in women exposed to aripiprazole during the embryonic period: A prospective multicentric cohort study. Poster presented at the VIIIeme Congres de Physiologie de Pharmacologie et de Therapeutique; 22-24 April 2013; Angers (France). p.26-05 Available from: http://www.atout-org.com/p2t2013/abstract-display!fr!!!!00af00da-8e7a-1030-b866-9251dd645b9d!2f878808-bcdf-1030-b866-9251dd645b9d [Accessed 17 April 2014]
53. Wichman CL. Atypical antipsychotic use in pregnancy: A retrospective review. Arch Womens Ment Health 2009;12:53-7
54. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome. A prospective, cohort study. J Clin Psychopharmacol 2013;33:453-62
55. Sadowski A, Todorow M, Brojeni PY, et al. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: A cohort study. BMJ Open 2013;3:e003062
56. Kulkarni J, Worsley R, Gilbert H, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One 2014;9:e94788
57. Windhager E, Kim SW, Saria A, et al. Perinatal use of aripiprazole. Plasma Levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol 2014. [Epub ahead of print]
58. Schlotterbeck P, Leube D, Kircher T, et al. Aripiprazole in human milk. Int J Neuropsychopharmacol 2007;10:433
59. Gentile S. Bipolar disorder and pregnancy: to treat or not to treat? BMJ 2012;345:e7367
60. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36:518-44
61. Sta°hl M, Edwards IR, Bowring G, et al. Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of National Pharmacovigilance Centres. Drug Saf 2003;26:721-7
62. Gentile S. Infant safety with antipsychotic therapy in breast-feeding. A systematic review. J Clin Psychiatry 2008;69:666-7
63. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetric outcomes. Am J Psychiatry 2007;164:1214-20
64. Hale T. Medication and mother's milk. 16th edition. Hale Publishing, Amarillo, TX; 2012
65. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28(8):1400-11
66. Coventry & Warwickshire. Area Prescribing Committee. Drug Positioning Statement. Abilify Maintena-. Available from: http://www.google.it/url? sa=t&rct=j&q=&esrc=s&source=web &cd=19&ved=0CGEQFjAIOAo&url= http%3A%2F%2Fwww. coventrywarksapc.nhs.uk%2Fmf.ashx% 3FID%3Dbf67bf8b-999b-499b-807b-56a3dfb82dfa&ei=-LqdU-SELOb E0QXq5YGYCQ&usg=AFQjCNFSP5 Pys-glmhpU-dd1lsJ4Ggergg [Accessed 19 July 2014]
67. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new typical antipsychotic: phase 2 clinical trial result. Eur Neuropsychopharmacol 1997;7(Suppl 2):227
68. Bristol-Myers Squibb. CN138-001: A multicenter, randomized, double-blind, placebo controlled study of three fixed doses of aripiprazole in the treatment of patients with acute schizophrenia [online]. 2001. Dated 27 July 2001. Available from: http://ctr.bms.com/pdf/CN138001.pdf [Accessed 26 July 2014]
69. Bristol-Myers Squibb. CN138-002 (26-52 week): A multicenter, randomized, double-blind safety and tolerability study of flexible doses of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia [online]. 2004a. Dated 1 December 2004 Available from: http://ctr.bms.com/pdf/CN138002.pdf [Accessed 17 July 2014]
70. Bristol-Myers Squibb. CN138-010: A multicenter, randomized, double-blind, placebo controlled study of aripiprazole in the maintenance treatment of patients with bipolar disorder [online]. 2003a. Dated17 December 2003 Available from: http:/ctr.bms.com/pdf/CN138010.pdf [Accessed 19 July 2014]
71. Bristol-Myers Squibb. CN138-087: A prospective, multicenter, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practices [online]. 2004d. Dated 29 April 2004 Available from: http://ctr.bms.com/pdf/CN138087. pdf [Accessed 27 July 2014]
72. Berman R, Fava M, Baker RA, et al. Metabolic effects of aripiprazole adjunctive therapy in major depressive disorder subpopulations (Studies CN138-139 and CN138-163). Presented at the Annual Meeting of American College of Neuropsychopharmacology; Boca Raton, Florida, USA; 2007a
73. Berman RM, Kaplita S, McQuade RD, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive Disorder (CN138-164). Presented at the Annual Meeting of the American Psychiatric Association; Washington, DC, USA; 2008
74. Bristol-Myers Squibb. A multicenter, double-blind, randomized, placebocontrolled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder. Dated 2006-2008 Available from: http://ctr.bms.com/pdf/CN138178.pdf [Accessed 30 July 2014]
75. Burris KD, Molski TF, Ryan E, et al. Aripiprazole is a high affinity partial agonist at human dopamine D2 receptors. Int J Neuropsychopharmacol 2000;3(Suppl 1):S129
76. Shapiro DA, Renock S, Arrington S, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11
77. Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT(1A) and 5-HT (2A) receptors: functional receptorbinding and in vivo electrophysiological study. Psychopharmacology (Berl) 2007;190:373-82
78. Keck PE, McElroy SL. Aripiprazole: A partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003;12:655-62
79. DrugLib.com. Drug Information Portal. Active ingredient: Aripiprazole-Basic Profile/Key Facts [homepage on the Internet]. Available from: http://www. druglib.com/activeingredient/aripiprazole/[Accessed 11 April 2014]
80. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612-27